Anti-RA33 Antibodies Are Present in Patients With Lyme Disease
Open Access
- 22 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 31 (2) , 65-70
Abstract
Background/Objective: To determine if anti-RA33 antibodies, which can be seen in early forms of inflammatory arthritis, are present in patients with Lyme arthritis (LA). Methods: Anti-RA33 antibodies were tested using a commercially available assay in patients with LA (n = 47) and compared with patients with erythema migrans who returned to health (EM RTH, n = 20) and those with post-treatment Lyme disease (PTLD) (n = 50), characterized by noninflammatory arthralgia, as an observational comparative study utilizing Lyme-exposed patients from various original cohorts. Results: We found that anti-RA33 was present in higher proportions of patients with LA (23.4% vs. 0%, p = 0.001) and PTLD (12.0% vs. 0%, p = 0.040) than healthy controls. There was also a trend toward a higher percentage of anti-RA33 positivity in patients with EM RTH versus controls (10.0% vs. 0%, p = 0.080). There were no statistically significant differences among groups of patients with LA, PTLD, and EM RTH (p ≥ 0.567). There was also no difference in the proportion of patients with antibiotic-responsive LA compared with those with persistent synovitis after antibiotics, termed post-infectious LA, and there were no differences in clinical manifestations, musculoskeletal ultrasound evaluation (synovial hypertrophy, power Doppler, tendinopathy), or patient-reported outcomes based on anti-RA33 status. Conclusions: This is the first study to identify anti-RA33 antibodies in patients with LA, though these antibodies did not identify a unique clinical subset of patients in this cohort. Unexpectedly, we found anti-RA33 antibodies at similar levels in patients with PTLD and EM RTH; further study is needed to determine the relevance of this finding.Keywords
This publication has 25 references indexed in Scilit:
- Lyme arthritis: linking infection, inflammation and autoimmunityNature Reviews Rheumatology, 2021
- Borrelia burgdorferipeptidoglycan is a persistent antigen in patients with Lyme arthritisProceedings of the National Academy of Sciences, 2019
- Autoantibody and metalloproteinase activity in early arthritisClinical Rheumatology, 2018
- Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritisJournal of Autoimmunity, 2016
- Antibodies to Endothelial Cell Growth Factor and Obliterative Microvascular Lesions in the Synovium of Patients With Antibiotic‐Refractory Lyme ArthritisArthritis & Rheumatology, 2014
- Therapy for Lyme arthritis: Strategies for the treatment of antibiotic‐refractory arthritisArthritis & Rheumatism, 2006
- Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind aBorrelia burgdorferipeptideJournal of Experimental Medicine, 2006
- Development of Autoantibodies before the Clinical Onset of Systemic Lupus ErythematosusNew England Journal of Medicine, 2003
- Association of Chronic Lyme Arthritis with HLA-DR4 and HLA-DR2 AllelesNew England Journal of Medicine, 1990
- Demonstration of a new antinuclear antibody (ANTI‐RA33) that is highly specific for rheumatoid arthritisArthritis & Rheumatism, 1989